Clinical trials
Glaucoma, Open-Angle trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
64 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2010 | 5 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 4 |
| 2022 | 3 |
| 2023 | 5 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Recruiting | 7 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
| Terminated | 4 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaukos Corporation | 7 |
| Allergan | 6 |
| iSTAR Medical | 5 |
| Implandata Ophthalmic Products GmbH | 4 |
| AbbVie | 3 |
| Ivantis, Inc. | 3 |
| Technische Universität Dresden | 3 |
| Transcend Medical, Inc. | 3 |
| Nova Eye, Inc. | 2 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma, Open-Angle | 64 |
| Glaucoma | 28 |
| Ocular Hypertension | 20 |
| Cataract | 5 |
| Low Tension Glaucoma | 3 |
| Exfoliation Syndrome | 2 |
| Eye Diseases | 2 |
| Astigmatism | 1 |
| Corneal Diseases | 1 |
| Dilatation, Pathologic | 1 |
Trials
Showing 51 to 64 of 64. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.